Remes, Anca
Wagner, Andreas H.
Schmiedel, Nesrin
Heckmann, Markus
Ruf, Theresa
Ding, Lin
Jungmann, Andreas
Senger, Frauke
Katus, Hugo A.
Ullrich, Nina D.
Frey, Norbert
Hecker, Markus
Müller, Oliver J. http://orcid.org/0000-0001-8223-2638
Funding for this research was provided by:
FAZIT Stiftung
Baden-Württemberg Stiftung
Deutsches Zentrum für Herz-Kreislaufforschung (81Z2700204, 81Z0700201)
Christian-Albrechts-Universität zu Kiel
Article History
Received: 4 August 2020
Accepted: 18 May 2021
First Online: 4 June 2021
Declarations
:
: A.R., A.H.W., A.J., H.A.K., M.H., and O.J.M. have filed a patent application on the therapeutic use of hpNFAT dON treatment in patients with cardiac hypertrophy and heart failure.
: Animal experiments were executed with approval of the local authorities in Kiel (permission number V312-7224.121-4 (75-6/14) and 1085) and Karlsruhe (G180/12).
: All authors approved the final manuscript and agreed to publication in Basic Research in Cardiology.